Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

Published:2007-07 Issue:4 Volume:17 Page:784-788
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

ALBERTS D.S.,LIU P.Y.,WILCZYNSKI S.P.,JANG A.,MOON J.,WARD J.H.,BECK J.T.,CLOUSER M.,MARKMAN M.

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Reference20 articles.

1. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

2. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and molecular features of platinum resistance in ovarian cancer;Critical Reviews in Oncology/Hematology;2024-09

2. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28

3. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023

4. Application of cancer stem cells in improving therapeutics;Nanotechnology Applications for Cancer Chemotherapy;2021

5. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer;Journal of Ovarian Research;2019-11-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP